Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Key facts
- Where
- Amiens, Besançon Cedex, Brest, Caen Cedex 9, Clermont-Ferrand cedex, Créteil, Lille Cedex, Nice, Nîmes, Paris, Poitiers, Toulouse cedex 9, and Valence, FranceSee the 14 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07292012, who can take part
Where in France
- Chu Amiens PicardieAmiens, FranceTaking people
- CHRU de BesançonBesançon Cedex, FranceTaking people
- CHU Brest Hôpital de la Cavale BlancheBrest, FranceTaking people
- Centre Hospitalier Universitaire De Caen NormandieCaen Cedex 9, FranceTaking people
- CHU Clermont-Ferrand - Hôpital d'EstaingClermont-Ferrand cedex, FranceTaking people
- APHP – Hôpitaux Universitaire Henri MondorCréteil, FranceTaking people
- Centre Hospitalier Universitaire De LilleLille Cedex, FranceTaking people
- CHU de Nice - Hopital de l'Archet 2Nice, FranceTaking people
- CHU NIMES CaremeauNîmes, FranceTaking people
- Hopital Saint LouisParis, FranceTaking people
- Institut Mutualiste MontsourisParis, FranceTaking people
- Centre Hospitalier Universitaire de PoitiersPoitiers, FranceTaking people
- CHU Toulouse - Hôpital RangueilToulouse cedex 9, FranceTaking people
- CH ValenceValence, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- Trial code
- NCT07292012EU 2025-521889-95-00
- Record updated
- 4 November 2026
- Original description
Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's DiseaseRead full original descriptionShow less
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease : EMINENT-CD
Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
Inclusion: Patients with CD; ≥ 18 to ≤ 75 years-old; Symptomatic CD according to PRO-2 (stool > 3 or abdominal pain score > 1); Transmural inflammation on baseline MRI (C-score > 0.5 in at least one segment).
Exclusion: Prior exposure to anti-p19 biological therapy; Exclude any previous use of p19 IL23s agents; Concomitant Clostridioides difficile infection; Exposure to more than 1 class of advanced therapies at a dose approved for the treatment of Crohn's disease (janus kinase [JAK] inhibitors, infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab, or approved biosimilars for these agents; HIV infection; Contra-indication to mirikizumab; Definitive ostomy; Colectomy with IPAA; Isolated or uncontrolled perianal lesions; Severe obstructive symptoms; Intra-abdominal abscess; Contra-indication to MRI; No health insurance; Pregnant or lactating women; Patients already included in biomedical research other than an observational study (e.g., registry, cohort); Patient under guardianship, curatorship or safeguard of justice.